Sonesitatug vedotin 在 CLDN18.2阳性晚期胃癌/胃食管结合部癌的二线及后线治疗中,显示出具有统计学显著性且重要临床意义的总生存期(OS)改善

美通社
Yesterday

研究结果有望将 CLDN18.2 阳性定义扩展至表达比例≥25%,这一人群约占该类患者的60%CLARITY-Gastric01是首个*在该治疗场景中显示抗CLDN18.2 ADC可带来总生存获益的 III 期临床试验这是阿斯利康全资拥有的ADC产品组合中公布的首个关键性研究结果 上海2026年7月28日 /美通社/ -- CLARITY-Gastric01全球III期临床试验公布的阳性结果显示,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10